Novo Nordisk A/S (NVO)
Pre-Market:
| Previous Close | 128.31 |
| Open | 127.80 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 800 |
| Day's Range | 127.50 - 130.13 |
| 52 Week Range | 75.56 - 138.28 |
| Volume | |
| Avg. Volume | 4,844,585 |
| Market Cap | 578.54B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 48.39 |
| EPS (TTM) | 2.67 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | 1.37 (1.06%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | 145.06 |
- Yahoo Finance Video
Apple, Novo Nordisk earnings, jobless claims: What to watch
A number of companies release their quarterly earning reports on Thursday, including Apple (AAPL), Novo Nordisk (NVO), Shell (SHEL), ConocoPhillips (COP), Cigna (CI), Coinbase (COIN), Moderna (MRNA), DraftKings (DKNG), Kellanova (K), United States Steel (X), and more. On the economic front, jobless claims for the week ending on April 27 will be released. Economists expect claims to rise to 212,000 from 207,000 the prior week. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Nicholas Jacobino
- Reuters
UPDATE 4-Novo Nordisk raises outlook fuelled by obesity drug demand
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before earnings on Thursday, on the back of Wegovy's popularity. It increased the amount of Wegovy it supplied to the U.S. market in the first quarter, CEO Lars Fruergaard Jorgensen told a media call.
ReutersNovo Nordisk raises outlook fuelled by obesity drug demand
LONDON (Reuters) -Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before earnings on Thursday, on the back of Wegovy's popularity. Sales growth in the U.S. was positively impacted by a one-off sales adjustment, the company said.
